- Home
- OLP vs EYPT Comparison
OLP vs EYPT Comparison
Compare OLP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | EYPT |
|---|---|---|
| Founded | 1982 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | OLP | EYPT |
|---|---|---|
| Price | $20.69 | $16.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 110.5K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 8.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $97,423,000.00 | $42,339,000.00 |
| Revenue This Year | $7.95 | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | ★ 9.29 | N/A |
| 52 Week Low | $19.62 | $3.91 |
| 52 Week High | $28.36 | $19.11 |
Technical Indicators
Market Signals| Indicator | OLP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 51.70 |
| Support Level | $19.94 | $16.67 |
| Resistance Level | $20.41 | $18.50 |
| Average True Range (ATR) | 0.35 | 0.98 |
| MACD | 0.00 | -0.23 |
| Stochastic Oscillator | 46.08 | 23.36 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.